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tacrolimus and ciclosporin, and a randomised study which assessed tacrolimus’
relapse prevention ability. Azathioprine and psoralen-UVA were considered as res-
cue therapies after failure of tacrolimus or ciclosporin. Effectiveness was measured
in quality-adjusted life years (QALY) and life years in remission (LYr). Only direct
costs (drugs, medical visits, hospitalization, adverse event treatment and monitor-
ing) were incorporated. The main source for unit costs was the Portuguese National
Health System price list whilst utilities were based on a survey conducted with DA
patients. Time horizon was fixed at 1 year. Probabilistic sensitivity analysis was
conducted with Monte Carlo simulations. RESULTS: For each 100 patients treated
with tacrolimus instead of ciclosporin, mean gains of 0.99 QALY (95%CI: [0.98; 1.00])
and 2.76 LYr (95%CI: [2.72; 2.81]) were estimated. Additionally, tacrolimus utiliza-
tion leads to an overall cost reduction of 16,277€ (95%CI: [-17,619; -15,607]) thus
representing a dominant option. CONCLUSIONS: When compared against
ciclosporin, tacrolimus is a cost-saving and more effective therapeutic option for
the treatment of moderate to severe AD from the Portuguese societal perspective.
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MODERATE AND SEVERE ATOPIC DERMATITIS: TWICE-DAILY MAINTENANCE
TREATMENT VERSUS STANDARD TWICE-DAILY REACTIVE TREATMENT OF
EXACERBATIONS FROM THE PERSPECTIVE OF THE SPANISH NATIONAL
HEALTH SERVICE
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OBJECTIVES:Atopic dermatitis (AD) is a chronic inflammatory itchy skin condition.
In a recent Spanish study the estimated prevalence of AD in children between 0 and
14 years old was 8.6%. Topical corticosteroids are currently the favoured treatment
for AD. However, their use is limited. Tacrolimus ointment has a demonstrated
efficacy in the treatment of moderate and severe AD in children. Twice-weekly
maintenance treatment has been approved and the aim of this study was to carry
out a cost-effective analysis comparing maintenance with standard reactive treat-
ment with tacrolimus ointment from the perspective of the Spanish NHS.
METHODS:An economic model was developed to compare maintenance and stan-
dard treatment patients for a period of 12 months. For those patients who discon-
tinued tacrolimus treatment before 1 year, resource use associated with post-dis-
continuation treatment was identified through a specially convened Advisory
Board with a group of clinical experts. Costs in 2012 euros were assigned to the
resources identified. Utility values were also inputted into the model. Results were
expressed in terms of total costs and cost/QALY. RESULTS: For patients with mod-
erate or severe AD, twice-weekly maintenance treatment with tacrolimus oint-
ment was shown to be more effective compared with the standard treatment reg-
imen. In the case of severe AD, maintenance treatment was also less costly
compared with standard treatment (939 vs. 1,084€). For moderate AD, the ICER was
1,981€/QALY which is considerably lower than the acceptable cost-effective
threshold (30,000€/QALY). CONCLUSIONS: Twice-weekly maintenance treatment
with tacrolimus ointment compared with standard reactive treatment would ap-
pear to be cost-effective and an additional option for clinicians for the treatment of
children suffering with moderate and severe AD in Spain.
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OBJECTIVES: To estimate the cost-effectiveness of linezolid for the treatment of
methicillin resistant staphylococcus aureus (MRSA) confirmed complicated skin
and soft tissue infections (cSSTI) under the Brazilian private health care system
perspective. METHODS: A cost-effectiveness analysis was developed based in a
decision tree model to simulate 28 days of treatment. A systematic revision of the
literature was developed over the efficacy and safety of the use of linezolid, van-
comicin, daptomicin and teicoplanin in patients diagnosed with MRSA-confirmed
cSSTI. Efficacy data used to input the economic model is informed in a published
meta-analysis. In this meta-analysis pooled efficacy estimates were generated
from clinical and microbiological determinations of success for the MRSA-sub-
groups in cSSTI clinical trials using a Bayesian meta-analytic approach (treatment
success rate: linezolide-84.4%, vancomicin-74.7%, daptomicina-78.1% and teico-
planina-74.7%). The treatment duration was 14 days for each first line treatment
and more 14 days for the second line treatment. Patients in treatment with lin-
ezolid stay 8 days in the hospital using venous linezolid and complete the treat-
ment with oral linezolid during 6 days, based on Itani et al. 2010. Patients in treat-
ment with vancomicin, daptomicin or teicoplanin stay 14 days in the hospital using
venous drugs. The costs and consequences of the disease treatment were com-
puted for each treatment alternative. Only direct medical costs were considered
based in official Brazilian costs databases. RESULTS: The incremental cost-effec-
tiveness analysis demonstrated that linezolide is the most economically attractive
drug, with better efficacy and lower cost than the comparators. The total cost per
patient with linezolide, vancomicin, daptomicin and teicoplanina were BRL26,365/
USD12,861, BRL36,421/USD17,766, BRL37,651/USD18,366, BRL37,984/USD18,529, re-
spectively. (US$ 1  R$ 2.05). CONCLUSIONS: Linezolid is the best therapeutic
option, with better efficacy and safety and lower cost, versus vancomicin, daptomi-
cin and teicoplanin for the treatment of patients diagnosed with MRSA-confirmed
cSSTI under Brazilian private perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of ranibizumab versus best sup-
portive care and grid laser photocoagulation therapy in patients with macular
edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO).
METHODS: A Markov model was developed to compare treatment with ranibi-
zumab to best supportive care (CRVO) and grid laser photocoagulation therapy
(BRVO) in patients with ME secondary to RVO. Data from the BRAVO and CRUISE
clinical trials were used to estimate transition probabilities between health states,
defined by best corrected visual acuity (BCVA) and the frequency of adverse events.
Costs and utilities from published sources were associated with each treatment
and the model health states, and these were combined to predict the incremental
costs and outcomes for a cohort treated over a lifetime horizon. The model in-
cluded the costs associated with fellow eye involvement and the cost of blindness.
A health system perspective in the UK was used. RESULTS: In CRVO, ranibizumab
lead to a gain of 0.539 QALYs at an incremental cost of £9,216. The incremental
cost-effectiveness ratio (ICER) was £17,103 per QALY. In BRVO, ranibizumab was
shown to produce a gain of 0.518 QALYs at an incremental cost of £8,141. The ICER
was £15,710 per QALY. Both results were below the threshold range of £20,000 to
£30,000 which is regarded as representing acceptable cost-effectiveness in the UK.
Probabilistic sensitivity analysis suggests that the probability of cost-effectiveness
for ranibizumab at a £20,000 threshold is 60% in CRVO and 57% in BRVO.
CONCLUSIONS: Ranibizumab is a cost-effective therapy for treating patients with
ME secondary to both BRVO and CRVO compared to current standard of care in the
UK (laser in BRVO and observation in CRVO).
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OBJECTIVES: The value of ranibizumab as compared to standard care (laser pho-
tocoagulation in BRVO and observation in CRVO) was assessed within the frame-
work of a cost-utility analysis (CUA) from the Canadian health care and societal
perspectives. METHODS: Cost-utility of ranibizumab to the Canadian health care
system was analyzed using a Markov model that followed a cohort of 66 or 68 year
old patients (with BRVO or CRVO) over a lifetime time horizon. The model included
8 heath states as defined by best corrected visual acuity (BCVA) and 1 absorbing
state for death. Year 1 health state transitions were based on data from the BRAVO
and CRUISE trials, while year 2 transitions were based on data from the HORIZON
extension trial. From year 3 onwards, health state transitions were based on fixed
probabilities of maintaining or worsening BCVA. Health state utilities were derived
from both the literature and a Canadian utility study in RVO patients. Resource use
and costs were collected from clinical trials, published literature, and standard
Canadian sources. Costs and outcomes were discounted at 5% as recommended by
Canadian guidelines. RESULTS: From the health care perspective, patients receiv-
ing ranibizumab for BRVO accrued an additional 0.22 quality-adjusted life years
(QALYs) with a total estimated incremental cost of CAD$8,080, resulting in $36,725
per QALY gained. In CRVO, 0.41 QALYs and $11,466 were estimated, resulting in
$28,046 per QALY gained. From the societal perspective, considering costs related
to productivity losses, the analyses resulted in an incremental cost per QALY
gained of $11,266 for BRVO and $2,103 for CRVO. CONCLUSIONS: Compared to
standard care (laser photocoagulation in BRVO and observation in CRVO), ranibi-
zumab shows cost-effectiveness within commonly accepted cost per QALY thresh-
olds from both the health care and societal perspectives.
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OBJECTIVES:Quantify the cost effectiveness of treatments for macular edema (ME)
secondary to branch or central retinal vein occlusion (BRVO, CRVO) from U.S. pay-
er/societal perspectives. METHODS: A Markov model consisting of five visual acu-
ity (VA) health states and death was developed to quantify clinical outcomes, costs,
and quality-adjusted life-years (QALYs) associated with no treatment (observation)
or two-year treatment with ranibizumab monotherapy (six monthly injections; as
needed thereafter), laser photocoagulation (BRVO only), ranibizumab plus laser
(BRVO only), triamciniolone acetonide (CRVO only), or dexamethasone intravitreal
implant. Transition probabilities were based on patient-level data for ranibizumab
( laser) and published literature for the remaining alternatives. Health state-
specific costs and utilities were accrued for 13 years—approximate median survival
of an RVO patient—with costs and QALYs discounted 3% annually. Costs associ-
ated with treatment, adverse events, and impaired vision were expressed in 2011
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U.S. dollars. Incremental cost-effectiveness ratios (ICERs) were calculated compar-
ing the least costly alternative to the next most costly strategy. Deterministic and
probabilistic sensitivity analyses were conducted. RESULTS: Ranibizumab demon-
strated superior efficacy relative to other strategies in both BRVO and CRVO but was
most costly ($26,732 and $32,850; BRVO and CRVO, respectively). Other strategy
costs ranged from $10,622 (observation in BRVO) to $16,090 (dexamethasone intra-
vitreal implant in CRVO patients). QALYs were greatest for ranibizumab (6.75 and
6.10; BRVO and CRVO, respectively) compared to a range of 4.88 (observation in
CRVO) to 5.93 (laser in BRVO). Dexamethasone intravitreal implant was dominated
in BRVO as was no treatment in CRVO. ICERs for ranibizumab were favorable
($19,270/QALY vs laser in BRVO; $34,204/QALY vs dexamethasone intravitreal im-
plant in CRVO). At a threshold of $50,000/QALY, probabilistic analyses suggested
ranibizumab to be cost effective in 99.7% (BRVO) and 88.3% (CRVO) of simulations.
CONCLUSIONS: In patients with ME secondary to BRVO or CRVO, ranibizumab is a
cost-effective treatment alternative.
SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: Retinal vein occlusion (RVO) is the second most common vascular
disorder of the retina, affecting approximately 28,000 new patients every year in
Canada, but little is known about their health utility. A Canadian Observational
Utility Study was conducted to estimate utility values for RVO patients with differ-
ent levels of visual acuity (VA). METHODS: A total of 202 participants with RVO,
where 37% had CRVO and 63% had BRVO, were enrolled from 20 sites across Can-
ada. Participantss had RVO in either their best-seeing eye (17%) or worse-seeing eye
(83%). Spectacle corrected VA was measured and patient health utility was col-
lected using the Health Utilities Index questionnaire (HUI3). VA was recorded as a
fraction (Snellen Score) and the value of this fraction was expressed as logMAR. A
linear regression model was used to predict utility values from logMAR in the
affected eye adjusting for key clinical covariates (age, duration of disease, logMAR
in fellow eye). The baseline characteristics of participants from randomized con-
trolled clinical trials (BRAVO, CRUISE) were used to generate predicted health util-
ities relevant in the context of these studies. RESULTS: For the 202 participants
(ages 39 to 92, median 72) the mean (SD) HUI utility value was 0.80 (0.20), ranging
from 0.18 to 1 (n169) and logMAR score was 0.62 (0.42), ranging from 0 to 1.60
(n202). The correlation between VA and utility was significant (r -0.21, p0.004,
n169) and the regression model indicated that a one unit increase in logMAR
score was associated with 0.085 unit decrease in utility. Based on the regression
model, HUI-based utilities decrease from 0.87 (logMAR -0.15) to 0.74 (logMAR 1.45)
for typical patients in the randomized studies (mean age67, logMAR fellow
eye0.09, disease duration3.4 months). CONCLUSIONS: RVO is a debilitating
ophthalmologic condition leading to reduced health utility with worsening of vi-
sual acuity.
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OBJECTIVES: Despite well-documented safety and tolerability issues associated
with traditional systemic therapies, many moderate and severe psoriasis patients
remain on these therapies. This analysis aims to assess levels of satisfaction and
quality of life in a biologic-eligible patient population currently receiving tradi-
tional systemic therapy. METHODS: Data were extracted from the Adelphi Real
World Psoriasis Disease-Specific Programme® (DSP), a cross-sectional survey of
dermatologists and their patients conducted in early 2011 in France, Germany,
Italy, Spain and the UK. Each dermatologist completed a comprehensive patient
record form (PRF) for their seven most recently seen psoriasis patients who met the
inclusion criteria. Patients were also invited to fill out a self-completion question-
naire, which included questions on satisfaction with treatment and various vali-
dated Health Related Quality of Life (HRQoL) instruments (EQ5D and DLQI). Patients
inclusion criteria were based on being eligible to receive biologic therapy; defined
by Body Surface Area ever exceeding 10%, ever having moderate or severe disease
(in the opinion of the physician), or ever having received a traditional systemic or
biologic treatment. RESULTS: Patient reported satisfaction levels show 58.7%
(n261) satisfied (SAT) and 41.3% (n184) dissatisfied (DIS) with current systemic
treatment. Analyses also suggested lower QoL amongst dissatisfied patients (all
reported figures have P-values 0.01; mean differences (MD) shown account for
confounding factors; age, severity and BSA). EQ-5D and DLQI scores indicated
poorer QoL amongst dissatisfied systemic patients, SAT 0.841 v DIS 0.672 (MD 0.124)
and SAT 5.14 v DIS 9.68 (MD 3.25), respectively. CONCLUSIONS: The analysis con-
ducted indicates that a number of patients remain dissatisfied with systemic treat-
ment. This dissatisfaction is associated with lower QoL, measured by both generic
and disease specific instruments. There is scope for additional investigation to
determine if alternate treatment pathways could improve both treatment satisfac-
tion and QoL for this patient group.
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OBJECTIVES: Despite well-documented safety and tolerability issues associated
with traditional systemic therapies, there remain barriers to biologic uptake in
many moderate and severe psoriasis patients. This analysis assesses the level of
treatment satisfaction with patient burden, namely work/activity impairment and
emotional wellbeing, in 445 patients currently receiving traditional systemic ther-
apy who are eligible for, but not receiving, biologic therapy. METHODS: Data were
extracted from the Adelphi Real World Psoriasis Disease-Specific Programme®, a
cross-sectional survey of 292 dermatologists and their patients conducted in early
2011 in France, Germany, Italy, Spain and the UK. Each dermatologist completed
patient record forms for their seven most recently seen patients. Patients were
invited to complete a questionnaire, including questions on satisfaction and vali-
dated instruments WPAI (Work Productivity and Activity Impairment) & PHQ9 (per-
sonal health questionnaire). Patient inclusion criteria were based on being eligible
to receive biologic therapy defined by: Body Surface Area ever exceeding 10%, ever
having moderate or severe disease (physician assessment), or ever having received
a traditional systemic or biologic treatment.RESULTS: Patient reported satisfaction
levels show 58.7% (n261) satisfied (SAT) and 41.3% (n184) dissatisfied (DIS) with
current treatment. Results from the WPAI questionnaire (n177) implied worse
average results for those dissatisfied with current treatment, DIS 30.40 v SAT 17.12
(Mean Difference (MD) -10.53). PHQ9 (n442) also found worse outcomes for dis-
satisfied patients; SAT 3.57 v DIS 6.01 (MD -1.94). All reported figures have P-values
0.05; MD incorporate confounding factors; age, severity and BSA. CONCLUSIONS:
This analysis provides insight into the divergence in burden of disease amongst
psoriasis patients, with patients dissatisfied with current systematic regimen suf-
fering greater implied levels of burden than satisfied patients. There is scope to
develop this further to better understand the implications of treatment dissatis-
faction in this population.
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OBJECTIVES: Patient-relevant endpoints play an important role in Health Technol-
ogy Assessment (HTA). There is a need to prioritize these endpoints according to
patients’ preferences. Our aim was to investigate how glaucoma patients prioritize
different aspects of their treatment including patient-relevant endpoints.
METHODS: The study included a feasibility test and the completion of a specific
questionnaire at the ophthalmology clinic of Bonn. Patients rated the importance
of different aspects of glaucoma treatment by a pairwise comparison. Relative
weights were generated for each aspect by Analytic Hierarchy Process (AHP), a
multi-criteria decision analysis method using matrix algebra. . Additionally the
EQ-5D was applied to stratify the patients into subgroups according to their stated
utility. RESULTS: The AHP yielded the following results (Weight, Mean, SD, CI) by
downwards order: 1. Autonomy (0.394, 0.371  0.145, 0.311 - 0.431), subdivided in
household chores (0.239, 0.275  0.258, 0.168 - 0.381) and outdoor mobility (0.761,
0.725 0.258, 0.619 - 0.832). 2. Reading and seeing details (0.229, 0.212 0.123, 0.161
- 0.263). 3. Darkness and glare (0.153, 0.165 0.111, 0.119 - 0.211). 4. Peripheral vision
(0.089, 0.085 0.058, 0.061 - 0.109). 5. Side effects (0.088, 0.115 0.131, 0.060 - 0.168),
and 6. Treatment-related burden (0.047, 0.052  0.06, 0.027 - 0.076). The observed
inconsistency reached a consistency ratio of 0.04 and did not exceed the limit of 0.1.
Subgroup analyses according to the EQ-5D stratification showed adaptation effects
and loss aversion. CONCLUSIONS: AHP can be used in HTA to give a quantitative
dimension to patients’ preferences for treatment aspects. Preference elicitation
could provide important information at various stages of HTA and challenge opin-
ions on the importance of treatment aspects or endpoints.
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OBJECTIVES: Empirical evidence for the efficacy of drugs and therapeutic proce-
dures has become crucial for reimbursement and for use in praxis. Beyond that,
assessment of patient benefit from the patient’s perspective is of particular rele-
vance. The PBI for skin diseases is a validated instrument developed to measure
patient-relevant benefits in dermatology. So far, no specific validation data on such
an instrument for psoriasis have been published. Objective of this study was the
validation of PBI specifically for psoriasis treatment. METHODS: Patient-relevant
treatment needs were recorded with the “Patient Needs Questionnaire” (PNQ) and
patient benefits from treatment were assessed using the “Patient Benefit Question-
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